217 related articles for article (PubMed ID: 25175066)
1. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Studer V; Rossi S; Motta C; Buttari F; Centonze D
J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066
[TBL] [Abstract][Full Text] [Related]
2. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Piccio L; Naismith RT; Trinkaus K; Klein RS; Parks BJ; Lyons JA; Cross AH
Arch Neurol; 2010 Jun; 67(6):707-14. PubMed ID: 20558389
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
Taupin P
Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
[TBL] [Abstract][Full Text] [Related]
4. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders.
Petereit HF; Rubbert-Roth A
Mult Scler; 2009 Feb; 15(2):189-92. PubMed ID: 18971221
[TBL] [Abstract][Full Text] [Related]
5. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials.
Bonnan M; Ferrari S; Bertandeau E; Demasles S; Krim E; Miquel M; Barroso B
Curr Drug Targets; 2014; 15(13):1205-14. PubMed ID: 25355180
[TBL] [Abstract][Full Text] [Related]
8. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.
Nielsen AS; Miravalle A; Langer-Gould A; Cooper J; Edwards KR; Kinkel RP
Mult Scler; 2012 Mar; 18(3):377-8. PubMed ID: 21828201
[No Abstract] [Full Text] [Related]
9. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
[TBL] [Abstract][Full Text] [Related]
10. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
Bar-Or A; Fawaz L; Fan B; Darlington PJ; Rieger A; Ghorayeb C; Calabresi PA; Waubant E; Hauser SL; Zhang J; Smith CH
Ann Neurol; 2010 Apr; 67(4):452-61. PubMed ID: 20437580
[TBL] [Abstract][Full Text] [Related]
11. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
[TBL] [Abstract][Full Text] [Related]
12. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Monson NL; Cravens PD; Frohman EM; Hawker K; Racke MK
Arch Neurol; 2005 Feb; 62(2):258-64. PubMed ID: 15710854
[TBL] [Abstract][Full Text] [Related]
13. Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis: Is Intrathecal Anti-CD20 a Therapeutic Option?
Fereidan-Esfahani M; Brück W; Weber MS
JAMA Neurol; 2015 Dec; 72(12):1407-8. PubMed ID: 26458194
[No Abstract] [Full Text] [Related]
14. Rituximab and multiple sclerosis.
Kitsos DK; Tsiodras S; Stamboulis E; Voumvourakis KI
Clin Neuropharmacol; 2012; 35(2):90-6. PubMed ID: 22421587
[TBL] [Abstract][Full Text] [Related]
15. Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS.
Pranzatelli MR; Tate ED; Travelstead AL; Verhulst SJ
Cytokine; 2011 Mar; 53(3):384-9. PubMed ID: 21211990
[TBL] [Abstract][Full Text] [Related]
16. The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Topping J; Dobson R; Lapin S; Maslyanskiy A; Kropshofer H; Leppert D; Giovannoni G; Evdoshenko E
Mult Scler Relat Disord; 2016 Mar; 6():49-53. PubMed ID: 27063622
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on anti-CD20.
Waubant E
Int MS J; 2008 Mar; 15(1):19-25. PubMed ID: 18713565
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Dunn N; Juto A; Ryner M; Manouchehrinia A; Piccoli L; Fink K; Piehl F; Fogdell-Hahn A
Mult Scler; 2018 Aug; 24(9):1224-1233. PubMed ID: 28762877
[TBL] [Abstract][Full Text] [Related]
20. B cells undergo unique compartmentalized redistribution in multiple sclerosis.
Haas J; Bekeredjian-Ding I; Milkova M; Balint B; Schwarz A; Korporal M; Jarius S; Fritz B; Lorenz HM; Wildemann B
J Autoimmun; 2011 Dec; 37(4):289-99. PubMed ID: 21924866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]